Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
Public ClinicalTrials.gov record NCT03257462. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
Study identification
- NCT ID
- NCT03257462
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 24 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 11, 2017
- Primary completion
- Mar 1, 2019
- Completion
- Mar 28, 2019
- Last update posted
- Oct 21, 2025
2017 – 2019
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Spruce Biosciences Clinical Site | Orange | California | 92123 | — |
| Spruce Biosciences Clinical Site | San Diego | California | 92123 | — |
| Spruce Biosciences Clinical Site | Melbourne | Florida | 32935 | — |
| Spruce Biosciences Clinical Site | Atlanta | Georgia | 30046 | — |
| Spruce Biosciences Clinical Site | Indianapolis | Indiana | 46202 | — |
| Spruce Biosciences Clinical Site | Ann Arbor | Michigan | 48109 | — |
| Spruce Biosciences Clinical Site | Minneapolis | Minnesota | 55414 | — |
| Spruce Biosciences Clinical Site | Las Vegas | Nevada | 89148 | — |
| Spruce Biosciences Clinical Site | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Congenital Adrenal Hyperplasia trials
Other public records listing Congenital Adrenal Hyperplasia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07611786: Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia Not yet recruiting
- NCT07144163: A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia Recruiting
- NCT04490915: Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia Active, not recruiting
- NCT07159841: A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) Recruiting
- NCT05669950: A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia Recruiting
- NCT04783181: A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03257462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03257462 live on ClinicalTrials.gov.